Shares of EnteroMedics Inc. (NASDAQ:ETRM) have been given a consensus broker rating score of 2.00 (Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. One research analyst has rated the stock with a hold recommendation and one has assigned a strong buy recommendation to the company.

Brokers have set a 12 month consensus target price of $1.10 for the company and are anticipating that the company will post ($0.50) EPS for the current quarter, according to Zacks. Zacks has also assigned EnteroMedics an industry rank of 110 out of 265 based on the ratings given to related companies.

Separately, Zacks Investment Research raised shares of EnteroMedics from a “hold” rating to a “buy” rating and set a $0.25 target price for the company in a report on Tuesday, August 9th.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at

Shares of EnteroMedics (NASDAQ:ETRM) traded up 0.095% on Thursday, reaching $0.105. 1,769,255 shares of the company were exchanged. The company’s market cap is $2.87 million. The company’s 50-day moving average price is $0.14 and its 200 day moving average price is $0.42. EnteroMedics has a 12 month low of $0.10 and a 12 month high of $4.95.

EnteroMedics (NASDAQ:ETRM) last announced its quarterly earnings data on Thursday, August 4th. The medical device company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.75) by $0.26. EnteroMedics had a negative net margin of 4,157.93% and a negative return on equity of 1,361.34%. On average, equities research analysts expect that EnteroMedics will post ($2.37) EPS for the current year.

About EnteroMedics

EnteroMedics Inc (EnteroMedics) is a medical device company. The Company is focused on the design and development of devices that use neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders. The Company’s neuroblocking technology, which is referred to as VBLOC therapy, is designed to intermittently block the vagus nerve.

5 Day Chart for NASDAQ:ETRM

Get a free copy of the Zacks research report on EnteroMedics (ETRM)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for EnteroMedics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for EnteroMedics Inc. and related companies with's FREE daily email newsletter.